Early Statin Use After Type 2 Diabetes Diagnosis Linked to Lower Dementia Risk

Starting statin treatment soon after a type 2 diabetes diagnosis was associated with a reduced risk of developing dementia, according to research presented at the ESC Congress 2026 and published in The Lancet Regional Health – Europe. Nearly half of dementia cases could theoretically be prevented by addressing 14 modifiable risk factors, according to the Lancet Commission, and managing cholesterol from midlife is one of them.

"Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," said presenter Dr Tummas Ternhamar of Copenhagen University Hospital, Denmark. High LDL-C is common among people with type 2 diabetes, and diabetes itself is a recognised risk factor for cognitive decline and dementia, so the researchers tested whether starting LDL-C-lowering statins early after a type 2 diabetes diagnosis was associated with lower dementia risk.

Using Danish national registers, the researchers identified 132,585 people who had not previously taken statins and who developed type 2 diabetes between 2006 and 2019. They were followed through the end of 2021 and split into three groups: those who started statins within one year of diagnosis, those who started between one and five years after diagnosis, and those who did not start statins within five years. Over a median follow-up of 7.1 years, 2.7% of participants developed dementia.

Compared with people who did not start statins, those who began within the first year had a 15% lower relative risk of dementia over 10 years, while those who started between one and five years after diagnosis had a 10% lower relative risk. The results were similar in women and men. Because the study was observational, the researchers said it cannot prove that statins prevent dementia — only that the two are associated.

Dr Ternhamar said statins "seem to be underused" in people with type 2 diabetes despite their established protective effect against cardiovascular disease, and that timely LDL-C treatment may offer "another potentially important reason" to prioritise it.